Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human MSH6 Anticorps:
anti-Mouse (Murine) MSH6 Anticorps:
anti-Rat (Rattus) MSH6 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal MSH6 Primary Antibody pour ELISA, WB - ABIN1724694
Lynch, Lynch: What the physician needs to know about Lynch syndrome: an update. dans Oncology (Williston Park, N.Y.) 2005
Show all 2 Pubmed References
Human Polyclonal MSH6 Primary Antibody pour ICC, IF - ABIN151794
Cyr, Heinen: Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding. dans The Journal of biological chemistry 2008
Show all 2 Pubmed References
Human Polyclonal MSH6 Primary Antibody pour IHC, IP - ABIN151795
Masih, Kunnev, Melendy: Mismatch Repair proteins are recruited to replicating DNA through interaction with Proliferating Cell Nuclear Antigen (PCNA). dans Nucleic acids research 2008
Show all 2 Pubmed References
Human Monoclonal MSH6 Primary Antibody pour ICC, FACS - ABIN969293
Grindedal, Møller, Eeles, Stormorken, Bowitz-Lothe, Landrø, Clark, Kvåle, Shanley, Maehle: Germ-line mutations in mismatch repair genes associated with prostate cancer. dans Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009
Human Monoclonal MSH6 Primary Antibody pour ELISA, WB - ABIN969292
Becker, Creagh, ONeill: Rab39a binds caspase-1 and is required for caspase-1-dependent interleukin-1beta secretion. dans The Journal of biological chemistry 2009
Human Monoclonal MSH6 Primary Antibody pour ELISA, WB - ABIN966596
Hess, Mendillo, Mazur, Kolodner: Biochemical basis for dominant mutations in the Saccharomyces cerevisiae MSH6 gene. dans Proceedings of the National Academy of Sciences of the United States of America 2006
Cow (Bovine) Polyclonal MSH6 Primary Antibody pour IHC, WB - ABIN2776759
Wedrén, Lovmar, Humphreys, Magnusson, Melhus, Syvänen, Kindmark, Landegren, Fermér, Stiger, Persson, Baron, Weiderpass: Estrogen receptor alpha gene polymorphism and endometrial cancer risk--a case-control study. dans BMC cancer 2009
our data suggests thatMSH6 Glu39Gly polymorphism is associated with the risk of developing sporadic colorectal cancer in polish population. Linkage to the female gender, onset above 60 years old and further increase of risk when combined with wild-type allele of PMS2 (Montrer PMS2 Anticorps) IVS1-1121C >
hMSH6 Glu39Gly polymorphism is associated with the risk of developing colorectal cancer in the Polish population.
Expression of MSH6 and MSH2 (Montrer MSH2 Anticorps) was positively associated with tumor volume doubling time. Gene expression was positively associated with ATR (Montrer ANTXR1 Anticorps) expression. Reduction of MSH6 and MSH2 (Montrer MSH2 Anticorps) expression at the messenger RNA and protein levels could be involved in direct Pituitary Adenoma proliferation by promoting cell-cycle progression or decreasing the rate of apoptosis through interference with the function of the ATR (Montrer ANTXR1 Anticorps)-Chk1 (Montrer CHEK1 Anticorps) pathway.
Our results suggest that increased expression of MSH6, or other MMR (Montrer MRC1 Anticorps), may be a new mechanism contributing to the acquired resistance during TMZ therapy; and may serve as an indicator to the resistance in GBM.
study to estimate frequency of point mutations and chromosomal rearrangements in 3 mismatch repair (MMR (Montrer MRC1 Anticorps)) genes MLH1 (Montrer MLH1 Anticorps), MSH2 (Montrer MSH2 Anticorps), and MSH6 among unselected patients with ovarian cancer; estimate that approximately 0.6% of unselected ovarian cancer patients have mutations in the MMR (Montrer MRC1 Anticorps) genes
MSH6 frameshift variants incompletely segregate with the Lynch syndrome phenotype in two families.
Patients with mutations 6 showed higher rate of achieving major molecular response than those<6 (P=0.0381). Mutations in epigenetic regulator, ASXL1 (Montrer ASXL1 Anticorps), TET2 (Montrer TET2 Anticorps), TET3 (Montrer TET3 Anticorps), KDM1A (Montrer KDM1A Anticorps) and MSH6 were found in 25% of patients. TET2 (Montrer TET2 Anticorps) or TET3 (Montrer TET3 Anticorps), AKT1 (Montrer AKT1 Anticorps) and RUNX1 (Montrer RUNX1 Anticorps) were mutated in one patient each. ASXL1 (Montrer ASXL1 Anticorps) was mutated within exon 12 in three cases
The MSH6 gene polymorphisms are likely to play an important role in the progression of AIDS in the northern Chinese population.
MSH6 mutations contribute to colorectal cancer susceptibility in Algerian families with suspected Lynch syndrome.
Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 (Montrer MKI67 Anticorps) expression.
Studied MSH6 gene expression in developing zebrafish and the influence of MSH6 expression on the production of mismatch binding factors.
Identification and characterization of novel knockout mutants of the three major MMR (Montrer MRC1 Anticorps) genes, mlh1 (Montrer MLH1 Anticorps), msh2 (Montrer MSH2 Anticorps), and msh6, in zebrafish that develop tumors at low frequencies.
we show that AID binds cooperatively with UNG and the mismatch repair proteins Msh2-Msh6 to Ig Smu and Sgamma3 regions
Data suggest that MSH6 protects B cells from neoplastic transformation by preserving genomic stability.
similar defects on switching in Msh2 (Montrer MSH2 Anticorps)(-/-), Msh2 (Montrer MSH2 Anticorps)(-/-)Msh6(-/-) and Msh2 (Montrer MSH2 Anticorps)(-/-)Msh6(-/-)Msh3 (Montrer MSH3 Anticorps)(-/-) mice confirm that MutSalpha but not MutSbeta plays an important role in class switch recombination
Msh6 deficiency resulted in somatic instability of a (GTG (Montrer GGT1 Anticorps))84 repeat.
role for Msh6 in protective cellular responses of primary cells to ultraviolet-B-induced mutagenesis and, hence, the prevention of skin cancer.
Data suggest that MutS homologues Msh2 (Montrer MSH2 Anticorps), Msh3 (Montrer MSH3 Anticorps), and Msh6 play overlapping and distinct roles during antibody diversification processes.
Data suggest that activation-induced cytidine deaminase (Montrer AICDA Anticorps) has limited entry points into V and S regions in vivo, and subsequent mutation requires Msh2 (Montrer MSH2 Anticorps)-Msh6, but not Msh3 (Montrer MSH3 Anticorps), and DNA polymerase (Montrer POLB Anticorps).
Mice nullizygous for both Msh2 (Montrer MSH2 Anticorps) and Msh3 (Montrer MSH3 Anticorps) and those nullizygous for both Msh3 (Montrer MSH3 Anticorps) and Msh6 displayed the greatest overall increases in mutation frequencies compared with wild-type mice.
in Msh6(-/-)Ung (Montrer UNG Anticorps)(-/-) mice, mutations were mostly C,G transitions and class switch recombination was greatly reduced.
p53 (Montrer TP53 Anticorps) and Msh6 are functionally interrelated and these tumor suppressors act together to accelerate tumorigenesis.
This gene encodes a protein similar to the MutS protein. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides, prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein of this gene combines with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene have been identified in individuals with hereditary nonpolyposis colon cancer (HNPCC) and endometrial cancer.
DNA mismatch repair protein Msh6
, G/T mismatch-binding protein
, mutS-alpha 160 kDa subunit
, sperm-associated protein
, mutS homolog 6 (E. coli)
, DNA mismatch repair protein Msh6-like
, g/T mismatch-binding protein
, LOW QUALITY PROTEIN: DNA mismatch repair protein Msh6